<DOC>
	<DOCNO>NCT02172157</DOCNO>
	<brief_summary>Primary objective : To determine basic pharmacokinetics BI 1744 BS , metabolite BI 1744 BS - glucuronide [ 14C ] -radioactivity include excretion mass balance , excretion pathway metabolism follow intravenous oral administration [ 14C ] BI 1744 CL Secondary objective : To determine safety tolerability follow intravenous oral administration [ 14C ] BI 1744 CL healthy male subject</brief_summary>
	<brief_title>Investigation Metabolism Pharmacokinetics 14CBI 1744 CL 14CBI 1744 CL Administered Oral Solution Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Olodaterol</mesh_term>
	<criteria>Healthy male accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( BP , PR ) , 12lead ECG , clinical laboratory test Age ≥18 ≤45 year Body mass index ( BMI ) ≥18.0 BMI ≤30.0 kg/m2 Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic , relevant acute infection History relevant allergy/hypersensitivity ( include allergy study drug excipients ) Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial Use drug might reasonably influence result trial base knowledge time protocol preparation within 10 day prior administration last sample Visit 2 collect Participation another trial investigational drug within two month prior administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke stay trial centre Alcohol abuse ( average 2 unit alcoholic beverage per day 14 unit per week ( 1 unit equal 1 pint [ 285 mL ] beer lager , 1 glass [ 125 mL ] wine , 25 mL shoot 40 % spirit ) ) Drug abuse Blood donation ( 100 mL within 60 day prior study drug administration trial ) Excessive physical activity ( within one week prior administration trial followup examination ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen study centre A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) Exclusion criterion specific study : Veins unsuitable infusion blood sample PR interval &gt; 220 m QRS interval &gt; 120 m Exposure radiation diagnostic reason ( except dental Xrays plain Xrays thorax bony skeleton ( exclude spinal column ) ) , work participation medical trial previous year Irregular defecation pattern ( less per 2 day ) The following exclusion criterion specific study due know class side effect profile β2mimetics : Asthma history pulmonary hyperreactivity Hyperthyrosis Allergic rhinitis need treatment Clinically relevant cardiac arrhythmia Paroxysmal tachycardia ( &gt; 100 beat per minute )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>